Shares of Teligent TLGT rose 11% in pre-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share rose 5.56% year over year to ($0.17), which missed the estimate of ($0.02).
Revenue of $15,967,000 lower by 4.83% year over year, which missed the estimate of $19,510,000.
Looking Ahead
Teligent hasn't issued any earnings guidance for the time being.
Teligent hasn't issued any revenue guidance for the time being.
How To Listen To The Conference Call
Date: Apr 08, 2020
Time: 08:05 AM ET
Webcast URL: https://edge.media-server.com/mmc/p/wv4e8pvd
Technicals
52-week high: $1.13
52-week low: $0.19
Price action over last quarter: down 47.57%
Company Profile
Teligent Inc is a specialty generic pharmaceutical company. Teligent develops, manufactures, and sells (under its own label) topical, injectable, complex, and ophthalmic pharmaceutical products in the U.S. and Canada. The product portfolio consists of hospital-based sterile injectable products and topical products (creams like Synalar and Spectazole; lotions like Kenalog; ointments like Topicort and Kenalog; and topical solutions like Pennsaid and Xylocaine). The company also offers services to the pharmaceutical, over-the-counter, and cosmetic markets.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.